RxDoctor Payments Data

Lyndsi Simmons, NP

Nurse Practitioner · Evansville, INNPI 1730844747

Payments from drug & device makers

$4,481in general payments, 2019–2025

Across 301 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$754
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$408
  • Axsome Therapeutics, Inc.$367
  • Otsuka America Pharmaceutical, Inc.$320
  • Lilly USA, LLC$272
  • plus $978 from 24 others

What the payments were for

  • Food & beverage$4,481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,481 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$15,483
Medicare patients
96
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan14$16,239
FarxigaDapagliflozin Propanediol13$15,070
MounjaroTirzepatide11$11,330
SynthroidLevothyroxine Sodium11$1,517
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$1,068
Duloxetine Hcl26$723
Levothyroxine Sodium75$676
Albuterol Sulfate HfaAlbuterol Sulfate27$494
Hydralazine Hcl11$490
Gabapentin28$456
Bupropion XlBupropion Hcl15$454
Buspirone Hcl21$436
Dicyclomine Hcl13$377
Pantoprazole Sodium23$306
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$19$16,23914 claims
AstraZenecaFarxiga$14$15,07013 claims
Lilly USA, LLCMounjaro$272$11,33011 claims
AbbVieSynthroid$1,380$1,51711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →